Abstract
The increasing frequency of multidrug-resistant bacteria and a recent slowing in the development of new antimicrobial agents place mankind in a state of emergency with regard to the threat of new bacterial infections. Antibacterial peptides (AMPs) are considered an important class of molecules to develop against bacteria. AMPs have been known for many years but very few have yet been extensively used in clinical practice, mainly because of their general toxicity and manufacturing cost. Now, thanks to new technologies for screening and development, interest in these molecules has grown. Many new AMPs have been discovered and some are under evaluation for the development of new antibacterial therapeutics. Here we review the major AMPs currently used in clinical practice and others in the phase of preclinical and clinical development.
Keywords: Antibiotic resistance, antimicrobial peptides, bacterial pathogens, clinical development, new antibacterials.
Current Protein & Peptide Science
Title:The Development of Antimicrobial Peptides as New Antibacterial Drugs
Volume: 14 Issue: 8
Author(s): Giulia Roscia, Chiara Falciani, Luisa Bracci and Alessandro Pini
Affiliation:
Keywords: Antibiotic resistance, antimicrobial peptides, bacterial pathogens, clinical development, new antibacterials.
Abstract: The increasing frequency of multidrug-resistant bacteria and a recent slowing in the development of new antimicrobial agents place mankind in a state of emergency with regard to the threat of new bacterial infections. Antibacterial peptides (AMPs) are considered an important class of molecules to develop against bacteria. AMPs have been known for many years but very few have yet been extensively used in clinical practice, mainly because of their general toxicity and manufacturing cost. Now, thanks to new technologies for screening and development, interest in these molecules has grown. Many new AMPs have been discovered and some are under evaluation for the development of new antibacterial therapeutics. Here we review the major AMPs currently used in clinical practice and others in the phase of preclinical and clinical development.
Export Options
About this article
Cite this article as:
Roscia Giulia, Falciani Chiara, Bracci Luisa and Pini Alessandro, The Development of Antimicrobial Peptides as New Antibacterial Drugs, Current Protein & Peptide Science 2013; 14 (8) . https://dx.doi.org/10.2174/138920371408131227155308
DOI https://dx.doi.org/10.2174/138920371408131227155308 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Malignant Hypertension: A Rare Problem or is it Underdiagnosed?
Current Vascular Pharmacology Plant-Derived Products as Antibacterial and Antifungal Agents in Human Health Care
Current Medicinal Chemistry COVID-19 and the Challenges of Chemotherapy: The Failure Case of Hydroxychloroquine in the Clinical Treatment of SARS-CoV-2 Infection
Coronaviruses Reducing the Development of Antibiotic Resistance in Critical Care Units
Current Pharmaceutical Biotechnology Prevention of Bacterial Endocarditis
Cardiovascular & Hematological Disorders-Drug Targets Probiotics: From Functional Foods to Pharmaceutical Products
Current Pharmaceutical Biotechnology Therapeutic Potential of Green Synthesized Metallic Nanoparticles Against <i>Staphylococcus aureus</i>
Current Drug Research Reviews Emerging Electrical Biosensors for Detecting Pathogens and Antimicrobial Susceptibility Tests
Current Organic Chemistry The Role of Beta-Blocker in Heart Failure in Adults with Congenital Heart Disease
Reviews on Recent Clinical Trials Current Developments in Anti-Fungal Agents
Current Medicinal Chemistry - Anti-Infective Agents Use of Diffusion- and Perfusion-Weighted Magnetic Resonance Imaging in Drug Development for Ischemic Stroke
Current Drug Targets - CNS & Neurological Disorders Coarctation of the Aorta - The Current State of Surgical and Transcatheter Therapies
Current Cardiology Reviews New Treatments for Emerging Cystic Fibrosis Pathogens other than Pseudomonas
Current Pharmaceutical Design Total Synthesis of ME1036 Starting from Readily Available Inexpensive Materials
Letters in Organic Chemistry HtrA Protease Family as Therapeutic Targets
Current Pharmaceutical Design Current Evidence on the Evaluation and Management of Fever Without a Source in Infants Aged 0-90 Days: A Review
Reviews on Recent Clinical Trials Beyond Hemostasis: The Role of Platelets in Inflammation, Malignancy and Infection
Cardiovascular & Hematological Disorders-Drug Targets <i>In Vitro</i> Evaluation of Immunogenicity of Recombinant OMP25 Protein Obtained from <i>Endemic Brucella</i> abortus Biovar 3 as Vaccine Candidate Molecule Against Animal Brucellosis
Protein & Peptide Letters Chemistry and Pharmacology of Neglected Helminthic Diseases
Current Medicinal Chemistry Bacteriophages and Phage-Derived Proteins – Application Approaches
Current Medicinal Chemistry